Ribo and Insilico Medicine Partner to Advance AI Guided siRNA Drug Development

Suzhou Ribo Life Science has entered a strategic collaboration with Insilico Medicine to accelerate siRNA drug development through the use of AI, announced in a press release. The partnership combines Ribo's experience in RNA interference drug research with Insilico's AI based drug discovery platforms.

The two companies will work together on target discovery, drug molecule design, optimization, and AI assisted clinical translation. Ribo has integrated AI into its siRNA drug development system, including an algorithm driven sequence design platform and a ligand screening platform that enables rapid identification and optimization of candidate molecules.

Insilico will contribute its Pharma.AI platform, which has recently been upgraded to support multiple scenarios in oligonucleotide drug development. The collaboration expands on previous joint work between the companies in intelligent autonomous high throughput screening.

Through this agreement, both companies aim to improve the efficiency and success rate of siRNA drug development and bring new therapies addressing unmet clinical needs to patients worldwide.